The country is clearly shaping its legislation to promote access to medicines by fostering generic production. INDIA'S approach to the revision of its Patents Act in 2005 is a clear example of a country shaping its legislation to promote access to medicines by fostering generic production. Although World Trade Organisation (WTO) rules made it mandatory for India to put in place a patent regime for medicines by 2005, nothing obliges...
More »SEARCH RESULT
Total Matching Records found : 59
Patent to plunder -Amit Sengupta
India's efforts to produce and supply life-saving drugs at affordable prices face challenges from multinational companies trying to “evergreen” their patents. THE average life expectancy across the globe has increased from around 30 years a century ago to over 65 years today. This has been made possible in large part by modern medicine. Never before in history have humans had access to such an array of medicines and devices to...
More »Mobiles can affect pacemakers: DoT by Kounteya Sinha
People with medical implants like pacemakers must not keep their cellphones on their shirt pockets. The latest directive by the department of telecommunication (DoT) says that "people having active medical implants should preferably keep the cellphone at least 15cm away from the implant." An office memorandum, circulated by the ministry of communications and IT on January 25, says manufacturer's mobile handset booklets will have to contain the safety precaution. MoS for communications and...
More »Research on Bhopal gas victims waits, not drug trials on them by Abantika Ghosh
The Indian Council of Medical Research (ICMR) has posted an advertisement inviting, by December 31, research proposals on long-term effects of methyl isocyanate (MIC) gas on Bhopal’s residents. However, while it is yet to conduct this research 27 years after the Bhopal gas tragedy caused by MIC that left hundreds dead, data shows that the “gas patients” have been routinely used for clinical trials for new drugs at the Bhopal Memorial...
More »Useless pharmaceutical studies cause real harm by Carl Elliott
Last month, the Archives of Internal Medicine published a scathing reassessment of a 12-year-old research study of Neurontin, a seizure drug made byPfizer. The study, which had included more than 2,700 subjects and was carried out by Parke-Davis (now part of Pfizer), was notable for how poorly it was conducted. The investigators were inexperienced and untrained, and the design of the study was so flawed it generated few if any...
More »
